

DAFTAR PUSTAKA

1. Ma J, Cao S. The epidemiology of nasopharyngeal carcinoma. In: Lu JJ, Cooper JS, Lee AWM, editors. *Nasopharyngeal Cancer: Multidisciplinary Management*. Germany: Springer; 2010. p.1-7
2. Jeyakumar A, Brickman TM, Jeyakumar A, Doerr T. Review of nasopharyngeal carcinoma. *ENT Journal*. 2006; 85(3): 168-73
3. Yenita, Asri A. Korelasi antara Latent Membrane Protein-1 Virus Epstein-Barr dengan P53 pada karsinoma nasofaring. *Jurnal Kes Andalas*. 2012; 1(1): 1-5
4. Ondrey FG, Wright SK. Neoplasms of the nasopharynx. In: Snow JB, Ballenger JJ, editors. *Otorhinolaryngology Head and Neck Surgery*, 16th ed, Ontario: BC Decker Inc; 2003. p.1392-407
5. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early detection of nasopharyngeal carcinoma. *Int J of Otolaryngol*. 2011; 2011: 1-6
6. Han BL, Xu XY, Zhang CZ, Wu JJ, Han CF, Wang H et al. Systemic review on Epstein-Barr Virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in asian populations. *Asian Pacific J Cancer Prev*. 2012; 13: 2577-81
7. Suzanna E, Sirait T, Rahayu PS, Shalmon G, Anwar E, Andalusia R, et al. Registrasi kanker berbasis rumah sakit di Rumah Sakit Dharmais-pusat kanker nasional 1993-2007. *Indonesia J Cancer. Suplemen 1*
8. Widodo AK, Farouk H, Willy S, Retnowati E. Clinico-pathological and serological (IgA anti VCA-anti EBNA) studies on nasopharyngeal carcinoma patients in Surabaya. *Folia Medica Indonesiana*. 2000; 36: 25-33
9. Rahman S, Subroto H, Novianti D. Clinical presentation of nasopharyngeal carcinoma in West Sumatra, Indonesia. *Proceeding of the 20th World Congress of IFOS, 2013. Seoul, Korea*.
10. Prasad U. Nasopharyngeal carcinoma: epidemiological review in relation to its etiology. *JUMMEC*. 1996; 1(2): 23-7
11. Lin CT. Relationship between Epstein-Barr Virus infection and nasopharyngeal carcinoma pathogenesis. *Chinese J Cancer*. 2009; 28(8): 1-14.
12. Hutajulu SH, Ng N, Jati BR, Fachiroh J, Herdini C, Hariwiyanto B, et al. Seroactivity against epstein-barr virus (EBV) among first degree relatives of sporadic EBV associated nasopharyngeal carcinoma in Indonesia. *J Med Virol*. 2012; 84: 768-76
13. Chan ATC, Teo PML, Johnson PJ. Nasopharyngeal carcinoma. *Ann of oncol*. 2002; 13: 1007-15
14. Zeng MS, Zeng YX. Pathogenesis and etiology of nasopharyngeal carcinoma. In: Lu JJ, Cooper JS, Lee AWM, editors. *Nasopharyngeal Cancer: Multidisciplinary Management*. Germany: Springer; 2010. p.9-25
15. Lou PJ, Hsu WL, Chien YC, Chen CJ. Screening and early diagnosis of nasopharyngeal carcinoma. In: Lu JJ, Cooper JS, Lee AWM, editors. *Nasopharyngeal Cancer: Multidisciplinary Management*. Germany: Springer; 2010. p.53-64
16. Gu AD, Mo HY, Xie YB, Peng RJ, Bei JX, Peng J, et al. Evaluation of a multianalyte assay and an enzyme linked immunosorbent assay for serological

- examination of Epstein-Barr virus specific antibody response in diagnosis of nasopharyngeal carcinoma. *Clin vaccine immunol.* 2008; 15(11): 1684-8
17. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, et al. Single assay combination of Epstein-Barr virus (EBV) EBNA-1 and viral capsid antigen p18 derived synthetic peptides for measuring anti EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients : option for field screening. *J Clin Microbiol.* 2006; 44(4): 1459-67
 18. Hsien YC, Abdullah MS, Telesinghe PU, Ramasamy R. Nasopharyngeal carcinoma in Brunei Darussalam : Low incidence among the Chinese and an evaluation of antibodies to Epstein-Barr Virus antigen as biomarkers. *Singapore Med J.* 2009; 50(4): 371-7
 19. Song C, Yang S. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of Nasopharyngeal Carcinoma. *Pak J Med Sci.* 2013; 29(3): 885-90
 20. Shimakage M, Dezawa T, Chatani M. Proper use of serum antibody against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow up. *Acta Otolaryngol.* 2000; 120: 100-4
 21. Chen H, Chi P, Wang W, Li L, Luo Y, Fu J, et al. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma. *Int J Infect Dis.* 2014; 25: 110-5
 22. Wong MMF, Lye MS, Cheng HM, Sam CK. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma. *Allergy imunol.* 2005; 23: 65-7
 23. Low WK, Leong JL, Goh YH, Fong KW. Diagnostic value of Epstein-Barr Viral serology in nasopharyngeal carcinoma. *Otolaryngol Head Neck Surg.* 2000; 123: 505-07
 24. Tsang RKY, Vlantis AC, Ho RWK, Tam JSL, Hasselt AV. Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: a three year institutional review. *Head and Neck.* 2004; :598-602
 25. Cai YL, Li J, Lu AY, Zheng YM, Zhong WM, Wang W, et al. Diagnostic significance of combined detection of Epstein-Barr virus antibody, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma. *APJCP.* 2014; 15: 2001-6
 26. Nikakhlagh S, Rahim F, Khodadadi A, Saki N. The association between Epstein-Barr virus with nasopharyngeal carcinoma in patients from southwestern region of Iran. *Int J Cancer Res.* 2010; 1: 1-6
 27. Chan CK, Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, et al. Epstein-Barr virus antibody patterns preseding the diagnosis of nasopharyngeal carcinoma. *Cancer causes and control.* 1991; 2: 125-31
 28. Ali MY. Histology of the human nasopharyngeal mucosa. *J Anat.* 1965; 99: 637-72
 29. Devi BCR, Pisani P, Tang TS, Parkin DM. High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. *Can Epidemiol Biomark Prev.* 2004 ; 13 : 482-6
 30. Hildesheim A, Dosemeci M, Chan CC, Chen CJ, Cheng YJ, Hsu MW, et al. Occupational exposure to wood, formaldehyde and solvents and risk of

- nasopharyngeal carcinoma. *J of Can Epidemiol, Biomark & Prev.* 2001; 10: 1145–53
31. Lo SS, Lu JJ. Natural history, presenting symptoms and diagnosis of nasopharyngeal carcinoma. In: Lu JJ, Cooper JS, Lee AWM, editors. *Nasopharyngeal Cancer: Multidisciplinary Management.* Germany: Springer; 2010. p.41-51
 32. Putti TC, Tan KB. Pathology of nasopharyngeal carcinoma. In: Lu JJ, Cooper JS, Lee AWM, editors. *Nasopharyngeal Cancer: Multidisciplinary Management.* Germany: Springer; 2010. P.71-80
 33. Wei KR, Xu Y, Liu J, Zhang WJ, Liang ZH. Histopathological classification of nasopharyngeal carcinoma. *Asian Pacific J Cancer Prev.* 2011; 12: 1141-7
 34. Breda E, Catarino RJF, Azevedo I, Lobao M, Monteiro E, Medeiros R. Epstein Barr Virus detection in nasopharyngeal carcinoma- implication in a low risk area. *Braz J Otorhinolaryngol.* 2010; 76(3): 310-5
 35. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, et al. Molecular diversity of Epstein-Barr virus IgG and IgA antibody response in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese and European subjects. *JID.* 2004; 190: 53-62
 36. Bray F, Haugen M, Moger TA, Tretli S, Aolen OO, Gretmol T. Age incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low risk populations and aetiologic implications. *Cancer Epidemiol Biomarkers Prev.* 2008; 17: 2356-65
 37. Pearson GR, Weiland LH, Neel B, Taylor W, Earle J, Mulroney SE, et al. Application of Epstein-Barr Virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. *Cancer J.* 1983; 51(2): 260-8
 38. Paschale MD, Clerici P. Serological diagnosis of Epstein-Barr Virus infection: Problems and solutions. *World J Virol.* 2012; 12(1): 31-43
 39. Cho WCS. Nasopharyngeal carcinoma : Molecular biomarker discovery and progress. *Mol Cancer.* 2007; 6(1): 1-9
 40. Tsao SW, Tsang CM, Pang PS, Zhang G, Chen H, Lo KW. The Biology of EBV infection in human epithelial cells. *Sem in Cancer Biol.* 2012; 22(2): 77-2
 41. Ocheni S, Olusina DB, Oyekunle AA, Ibegbulam OG, Kroger N, Bacher U, Zander AR. EBV-associated malignancies. *The Open Infect Dis J.* 2010; 4: 101-12
 42. Liao LJ, Lai MS. Epstein-Barr Virus serology in the detection and screening of nasopharyngeal carcinoma. In: *Carcinogenesis, Diagnosis and Molecular Targeted Treatment for Nasopharyngeal Carcinoma.* China: In Tech; 2012. p.83-94.
 43. Tiwawech D, Srivatanakul P, Karaluk A, Ishida T. Significance of Plasma IgA and IgG Antibodies to Epstein-Barr Virus Early and Viral Capsid Antigens in Thai Nasopharyngeal Carcinoma. *Asian Pacific J Cancer Prev* 2003 ; 4 : 113-8
 44. Shan L, Yan D, Xi L, Pei CQ, Cheng LX, Xue Q. Diagnostic value of Epstein Barr Virus capsid antigen-IgA in nasopharyngeal carcinoma : a meta analysis. *Chin Med J.* 2010; 123(9): 1201-5
 45. Mokhtari M, Hashemi JM, Davarpanah JAH. Prevalence of anti EBV antibodies in adult patients with nasopharyngeal carcinoma during 2003-2007 in Ishafan, Iran. *Iranian J Cancer Prev.* 2008; 1(4): 173-7

46. Tiwawech D, Chindavijak S, Saelee P, Sukarayodhin S, Ishida T, Ng PS. Detection of IgA antibody against Epstein-Barr Virus Nuclear Antigen 1 in nasopharyngeal carcinoma patients by ELISA. *Thai Cancer J.* 2008; 28(2): 83-92
47. Leung SF, Tam JS, Chan ATC, Zee B, Chan LYS, Huang DP et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr Virus DNA and anti-Epstein-Barr Viral Capsid Antigen IgA antibody. *Clin Chemistry.* 2004; 50(2): 339-45
48. Lo S, Ho WK, Wei WI. Outcome of patient with positive Epstein-Barr Virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong. *Arc Otolaryngol Head Neck Surg.* 2004; 130: 770-72
49. Thompson MP, Kurzrock R. Epstein Barr Virus and cancer. *Clin Cancer Res J.* 2004; 10: 803-21
50. Hausen HZ. Gammaherpesvirinae (Lymphocryptoviruses). In: *Infection Causing Human Cancer.* Germany: Wiley-VCH Verlag GmbH and Co; 2006. p.65-117.
51. Cohen JI. Virology and Molecular Biology of Epstein-Barr Virus. In: Tselis A, Jenson HB, editors. *Epstein-Barr Virus*, New York: Taylor and Francis Group; 2006. p.21-37
52. Cohen JI. Epstein Barr Virus infection. *NEJM.* 2000; 343(7): 481-92
53. Korcum AF, Ozyar E, Ayhan A. Epstein-Barr Virus gene and nasopharyngeal cancer. *Turkish J of Cancer.* 2006; 36: 97-107
54. Epstein-Barr Virus. (imaged on internet) cited on March 14th 2013. Available from: <http://www.cullenlab.duhs>.
55. Zheng H, Li L, Hu D, Deng X, Cao Y. Role of Epstein-Barr Virus encoded Latent Membrane Protein-1 in the carcinogenesis of nasopharyngeal carcinoma. *J Cell and Mol Immunol.* 2007; 4(3): 185-96.
56. Gullo C, Low WK, Teoh G. Association of Epstein-Barr Virus with nasopharyngeal carcinoma and current status of development of cancer-derived cell lines. *Ann Acad of Med J.* 2008; 37(9): 769-77.
57. Niedobitek G. Epstein-Barr Virus infection in the pathogenesis of nasopharyngeal carcinoma. *J Clin Pathol.* 2000; 53: 248-54.
58. Tulalamba W, Janvilisri T. Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers. *Int J Cell Biol.* 2012; 2012: 1-10
59. Lin CT, Lin CR, Tan GK, Chen W, Dee AN, Chan WY. The mechanism of Epstein-Barr Virus infection in nasopharyngeal carcinoma cells. *Am J Pathol.* 1997; 150(5): 1745-56
60. Tsao SW, Lo KW, Huang DP. Nasopharyngeal Carcinoma. In: Tselis A, Jenson HB, editors. *Epstein-Barr Virus*. New York: Taylor and Francis Group; 2006. p.273-98
61. Hsu MM, Sheen TS, Ko JY, Lou PJ. Clinical application of two new serological tests of Epstein-Barr virus in nasopharyngeal carcinoma. *J Chinese Oncol Soc.* 2001; 17(2): 17-25
62. Sela GB, Kuten A, Minkov I, Ari EG, Izhak OB. Prevalence and relevance of EBV latency in nasopharyngeal carcinoma in Israel. *J Clin Pathol.* 2004; 57: 290-3

63. Yap YY, Hasan C, Chan M. Epstein Barr Virus DNA detection in the diagnosis of nasopharyngeal carcinoma. *Otolaryngol Head Neck Surg.* 2007; 35: 986-91
64. Krishna SM, James S, Sreelekha TT, Kattoor J, Balaram P. Primary nasopharyngeal cancer of Indian origin and the viral link-a preliminary study. *Austral-Asian J Can.* 2006; 5(4): 241-52
65. Dolcetti R, Guidoboni M, Gloghini A, Carbone A. EBV-associated tumors: pathogenic insight for improved disease monitoring and treatment. *Curr Can Ther Rev J.* 2005; 1: 27-44
66. Kantakamalakul W, Chongkolwatana C, Naksawat P, Muangsomboon S, Sukpanichnant S, Chongvisal S et al. Specific IgA antibody to Epstein-Barr Viral Capsid Antigen: a better marker for screening nasopharyngeal carcinoma than EBV DNA detection by polymerase chain reaction. *Asian Pasific J Aller and Immunol.* 1999; 18: 221-6
67. Shao JY, Li YH, Gao HY. Comparison of plasma Epstein-Barr Virus (EBV) DNA levels and serum EBV immunoglobulin A/Virus Capsid Antigen antibody titers in patient with nasopharyngeal carcinoma. *Cancer J.* 2004; 100: 1162-70
68. Adam AAM, Abdullah NE, Khalifa EH, Elhasan LAM, Elamin EM, Hamad KM, et al. Pathology of nasopharyngeal carcinoma in Sudanese patients and its association with Epstein Barr Virus: a report from a single center in Khartoum. *Libertas Academica J.* 2011; 2: 1-6
69. Hutajulu SH, Indrasari SR, Indrawati LP, Harijadi A, Duin S, Haryana SM, et al. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. *Mol Can J.* 2011; 10(48): 1-9
70. Dahlan MS. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. Edisi kedua. Salemba Medika: Jakarta; 2009
71. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs and symptoms at presentation. *Chin J Cancer.* 2012; 31(4): 185-96
72. Sun R, Wang X, Li X. Correlation analysis of nasopharyngeal carcinoma TNM staging with serum EA IgA and VCA IgA and VEGF-C and -D. *Med Sci Monit.* 2015; 21: 2105-9